ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Université de Montréal gains access to ERS Genomics’ CRISPR/Cas9 patents, launching platforms for genome-wide screening and fostering research collaborations.

Mount Sinai mounted aggressive campaign to stifle debate over revelations about its controversial brain research

Audrey Carleton, Bruce Gil, Emily Nadal, and Zachary Smith contributed reporting. Support for this project was provided by the Fund for Investigative Journalism. Mount Sinai,

July 31, 2024

MSOS Stock Soared on Federal Legalization – What’s next for MSOS Stock

August 30, 2023

Rona Therapeutics secures funds for siRNA pipeline expansion

The company will use the investment proceeds to develop next-generation RNA platforms. Credit: FOTOGRIN / Shutterstock. Rona Therapeutics has secured $35m in its Series A+

July 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.